Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MorphoSys
Biotech
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years.
Nick Paul Taylor
Oct 29, 2024 6:16am
Novartis only wanted pelabresib, but MorphoSys had other ideas
Apr 12, 2024 8:53am
Novartis will pay €2.7B to pick up cancer specialist MorphoSys
Feb 5, 2024 7:06pm
Third Rock adds 3 new venture partners, including Karuna’s Paul
Jan 25, 2024 10:35am
MorphoSys fails secondary in blood cancer trial, sinking stock
Nov 21, 2023 5:52am
HI-Bio's expectations elevated by phase 2 autoimmune readouts
Apr 11, 2023 6:00am